(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 25.58% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 135.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Eton Pharmaceuticals's revenue in 2025 is $71,141,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2025 to be $2,168,009,982, with the lowest ETON revenue forecast at $2,057,789,913, and the highest ETON revenue forecast at $2,249,186,660. On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $2,812,354,895, with the lowest ETON revenue forecast at $2,657,027,733, and the highest ETON revenue forecast at $2,988,009,750.
In 2027, ETON is forecast to generate $3,778,054,331 in revenue, with the lowest revenue forecast at $3,316,792,729 and the highest revenue forecast at $4,258,892,733.